Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

J-E Gottenberg, L Guillevin, O Lambotte, B Combe, Y Allanore, A Cantagrel, C Larroche, M Soubrier, L Bouillet, M Dougados, O Fain, D Farge, X Kyndt, O Lortholary, C Masson, B Moura, P Remy, T Thomas, D Wendling, J-M Anaya, J Sibilia, X Mariette, Club Rheumatismes et Inflammation (CRI), J-E Gottenberg, L Guillevin, O Lambotte, B Combe, Y Allanore, A Cantagrel, C Larroche, M Soubrier, L Bouillet, M Dougados, O Fain, D Farge, X Kyndt, O Lortholary, C Masson, B Moura, P Remy, T Thomas, D Wendling, J-M Anaya, J Sibilia, X Mariette, Club Rheumatismes et Inflammation (CRI)

Abstract

Objective: To assess the tolerance and efficacy of rituximab in patients with various autoimmune diseases seen in daily rheumatological practice.

Methods: 866 rheumatology and internal medicine practitioners were contacted by e-mail to obtain the files of patients treated with rituximab for systemic autoimmune diseases. Patients with lymphoma were analysed if the evolution of the autoimmune disease could be evaluated.

Results: In all, 43 of 49 cases could be analysed, including 14 with rheumatoid arthritis (RA), 13 with systemic lupus erythematosus (SLE), six with primary Sjogren's syndrome (pSS), five with systemic vasculitis, and five with other autoimmune diseases. Rituximab was prescribed for lymphoma in two patients with RA and two with pSS. In the 39 other cases, rituximab was given because of the refractory character of the autoimmune disease. The mean follow up period was 8.3 months (range 2 to 26). There were 11 adverse events in 10 patients and treatment had to be discontinued in six. Efficacy was observed in 30 patients (70%): RA 11, SLE 9, pSS 5, vasculitis 2, antisynthetase syndromes 2, sarcoidosis 1. The mean decrease in corticosteroid intake was 9.5 mg/d (range 0 to 50) in responders. Seven patients experienced relapse after mean 8.1 months (5 to 15). Three patients died because of refractory autoimmune disease.

Conclusions: Despite absence of marketing authorisation, rituximab is used to treat various refractory autoimmune diseases in daily rheumatological practice. This study showed good tolerance and short term clinical efficacy, with marked corticosteroid reduction in patients with SLE, pSS, vasculitis, and polymyositis.

References

    1. J Exp Med. 2000 Aug 21;192(4):475-82
    1. Arthritis Rheum. 2005 Feb;52(2):601-7
    1. Arthritis Rheum. 2001 Jul;44(7):1717-8
    1. Arthritis Rheum. 2001 Dec;44(12):2836-40
    1. Br J Haematol. 2002 Feb;116(2):465-7
    1. Arthritis Rheum. 2002 Aug;46(8):2252-4; author reply 2254-5
    1. Am J Hematol. 2002 Aug;70(4):329
    1. Arthritis Rheum. 2002 Oct;46(10):2673-7
    1. Blood. 2003 May 15;101(10):3818-26
    1. Arthritis Rheum. 2003 Jun 15;49(3):394-8
    1. Arthritis Rheum. 2003 Aug;48(8):2146-54
    1. Lupus. 2003;12(10):779-82
    1. Ann Oncol. 2003 Dec;14(12):1792
    1. Rheumatology (Oxford). 2004 Feb;43(2):244
    1. N Engl J Med. 2004 Jun 17;350(25):2572-81
    1. Rheumatology (Oxford). 2004 Aug;43(8):1050-3
    1. Arthritis Rheum. 2004 Aug;50(8):2580-9
    1. J Immunol. 1994 Feb 1;152(3):1453-61
    1. Nat Immunol. 2000 Dec;1(6):475-82

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe